Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/50727 |
Resumo: | Inclui os dados de pesquisa. |
| id |
CRUZ_b05ad96d7f90e88faa45a7835e5adca4 |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/50727 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Silva, Thiago CerqueiraOliveira, Vinicius de AraújoBoaventura, Viviane S.Pescarini, JuliaBertoldo Júnior, JuracyMachado, Tales MotaOrtiz, Renzo FloresPenna, Gerson OliveiraIchihara, Maria YuryBarros, Jacson Venâncio deBarreto, Maurício LimaWerneck, Guilherme LoureiroBarral Netto, Manoel2022-01-11T13:11:24Z2022-01-11T13:11:24Z2022CERQUEIRA-SILVA, Thiago et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study. The Lancet Regional Health: Americas, [s.l.], v. 6, n. 100154, p. 1-11, Feb. 2022.2667-193Xhttps://www.arca.fiocruz.br/handle/icict/5072710.1016/j.lana.2021.100154Inclui os dados de pesquisa.Este estudo foi parcialmente financiado por uma doação do programa "Fazer o bem faz bem".Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Laboratório de Enfermidades Infecciosas Transmitidas por Vetores. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Laboratório de Enfermidades Infecciosas Transmitidas por Vetores. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Laboratório de Enfermidades Infecciosas Transmitidas por Vetores. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para Saúde. Salvador, BA, Brasil / London School of Hygiene and Tropical Medicine. London, United Kingdom.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para Saúde. Salvador, BA, Brasil.Universidade Federal de Ouro Preto. Ouro Preto, MG, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para Saúde. Salvador, BA, Brasil.Fundação Oswaldo Cruz. Escola de Governo Fiocruz Brasília. Brasília, DF, Brasil / Universidade de Brasília. Núcleo de Medicina Tropical. Brasília, DF, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para Saúde. Salvador, BA, Brasil. Universidade de São Paulo. São Paulo, SP, Brasil.Universidade de São Paulo. Faculdade de Medicina. Departamento de Patologia. São Paulo, SP, Brasil.Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para Saúde. Salvador, BA, Brasil.Universidade do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Inflamação e Biomarcadores. Laboratório de Enfermidades Infecciosas Transmitidas por Vetores. Salvador, BA, Brasil / Universidade Federal da Bahia. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Centro de Integração de Dados e Conhecimento para Saúde. Salvador, BA, Brasil.Background: Aging influences COVID-19 severity and response to vaccination, but previous vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within the elderly age group. Here we analyzed the impact of age on viral vector and inactivated virus vaccines' effectiveness, the main platforms used in low- and middle-income countries. Methods: We report a retrospective longitudinal study of 75,919,840 Brazilian vaccinees from January 18 to July 24, 2021, evaluating documented infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19-related hospitalisation, ICU admission, and death. Negative binomial regression models adjusted for sociodemographic characteristics were used for VE estimation. Findings: The overall analyzes of full vaccination showed VE against hospitalisation, ICU admission, and death of 91¢4% (95%CI:90¢1−92¢5), 91¢1% (95%CI:88¢9−92¢9) and 92¢3% (95%CI:90¢5−93¢7) for Vaxzevria and 71¢2% (95%CI:70¢0−72¢4), 72¢2% (95%CI:70¢2−74¢0) and 73¢7% (95%CI:72¢1−75¢2) for CoronaVac, respectively. VE for all outcomes is progressively lower with age. In fully-Vaxzevria-vaccinated individuals aged <60 years, VE against death was 96.5% (95%CI:82.1−99.3) versus 68¢5% (95%CI:40¢0−83¢4) in those ≥90 years. Among fully-CoronaVac-vaccinated individuals, VE against death was 84.8% (95%CI:77.1−89.9) in those <60 years compared to 63.5 (95%CI 58.7−67.7) for vaccinees aged 80−89 years and 48¢6%; (95%CI:35¢0−59¢3) for individuals aged ≥90 years. Post-vaccination daily cumulative incidence curves for all outcomes showed increased risk from younger to elder decades of life. There was no increase in the incidence of hospitalisation for individuals <60 years vaccinated during the same period as those aged ≥90 years. Interpretation: Although both vaccines have been effective in protecting against infection, hospitalization and death; Vaxzevria and CoronaVac demonstrated high effectiveness against severe outcomes for individuals up to 79 years of age. Our results reinforce the idea that booster doses should be carefully considered in elders.engElsevierCOVID-19VaccinesVaccinesCOVID-19VaccineCoronaVacVaxzevriaEffectivenessCoronavirusCOVID-19VacinasEfetividadeVacinasInfluence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83074https://www.arca.fiocruz.br/bitstream/icict/50727/1/license.txtd3e717dbb24bfc607ede047f44d29a0eMD51ORIGINALve_Thiago_Silva_FiocruzBSB_2022.pdfve_Thiago_Silva_FiocruzBSB_2022.pdfArtigoapplication/pdf673257https://www.arca.fiocruz.br/bitstream/icict/50727/2/ve_Thiago_Silva_FiocruzBSB_2022.pdfd1d9202cf49e24b5b2cf95b4fb50bf9dMD52ve_Thiago_Silva_FiocruzBSB_2022.docxve_Thiago_Silva_FiocruzBSB_2022.docxDados de pesquisaapplication/vnd.openxmlformats-officedocument.wordprocessingml.document754471https://www.arca.fiocruz.br/bitstream/icict/50727/3/ve_Thiago_Silva_FiocruzBSB_2022.docx002483975204678852573f9b9dce3b46MD53icict/507272023-02-15 22:58:17.424oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-02-16T01:58:17Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study |
| title |
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study |
| spellingShingle |
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study Silva, Thiago Cerqueira COVID-19 Vaccines Vaccines COVID-19 Vaccine CoronaVac Vaxzevria Effectiveness Coronavirus COVID-19 Vacinas Efetividade Vacinas |
| title_short |
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study |
| title_full |
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study |
| title_fullStr |
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study |
| title_full_unstemmed |
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study |
| title_sort |
Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study |
| author |
Silva, Thiago Cerqueira |
| author_facet |
Silva, Thiago Cerqueira Oliveira, Vinicius de Araújo Boaventura, Viviane S. Pescarini, Julia Bertoldo Júnior, Juracy Machado, Tales Mota Ortiz, Renzo Flores Penna, Gerson Oliveira Ichihara, Maria Yury Barros, Jacson Venâncio de Barreto, Maurício Lima Werneck, Guilherme Loureiro Barral Netto, Manoel |
| author_role |
author |
| author2 |
Oliveira, Vinicius de Araújo Boaventura, Viviane S. Pescarini, Julia Bertoldo Júnior, Juracy Machado, Tales Mota Ortiz, Renzo Flores Penna, Gerson Oliveira Ichihara, Maria Yury Barros, Jacson Venâncio de Barreto, Maurício Lima Werneck, Guilherme Loureiro Barral Netto, Manoel |
| author2_role |
author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Silva, Thiago Cerqueira Oliveira, Vinicius de Araújo Boaventura, Viviane S. Pescarini, Julia Bertoldo Júnior, Juracy Machado, Tales Mota Ortiz, Renzo Flores Penna, Gerson Oliveira Ichihara, Maria Yury Barros, Jacson Venâncio de Barreto, Maurício Lima Werneck, Guilherme Loureiro Barral Netto, Manoel |
| dc.subject.mesh.pt_BR.fl_str_mv |
COVID-19 Vaccines Vaccines |
| topic |
COVID-19 Vaccines Vaccines COVID-19 Vaccine CoronaVac Vaxzevria Effectiveness Coronavirus COVID-19 Vacinas Efetividade Vacinas |
| dc.subject.en.pt_BR.fl_str_mv |
COVID-19 Vaccine CoronaVac Vaxzevria Effectiveness |
| dc.subject.decs.pt_BR.fl_str_mv |
Coronavirus COVID-19 Vacinas Efetividade Vacinas |
| description |
Inclui os dados de pesquisa. |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-01-11T13:11:24Z |
| dc.date.available.fl_str_mv |
2022-01-11T13:11:24Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
CERQUEIRA-SILVA, Thiago et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study. The Lancet Regional Health: Americas, [s.l.], v. 6, n. 100154, p. 1-11, Feb. 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/50727 |
| dc.identifier.issn.pt_BR.fl_str_mv |
2667-193X |
| dc.identifier.doi.none.fl_str_mv |
10.1016/j.lana.2021.100154 |
| identifier_str_mv |
CERQUEIRA-SILVA, Thiago et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study. The Lancet Regional Health: Americas, [s.l.], v. 6, n. 100154, p. 1-11, Feb. 2022. 2667-193X 10.1016/j.lana.2021.100154 |
| url |
https://www.arca.fiocruz.br/handle/icict/50727 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/50727/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/50727/2/ve_Thiago_Silva_FiocruzBSB_2022.pdf https://www.arca.fiocruz.br/bitstream/icict/50727/3/ve_Thiago_Silva_FiocruzBSB_2022.docx |
| bitstream.checksum.fl_str_mv |
d3e717dbb24bfc607ede047f44d29a0e d1d9202cf49e24b5b2cf95b4fb50bf9d 002483975204678852573f9b9dce3b46 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813009291566645248 |